Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Capital Expenditures: 2022-2025

Historic Capital Expenditures for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to $27,000.

  • Phathom Pharmaceuticals' Capital Expenditures fell 38.64% to $27,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $147,000, marking a year-over-year decrease of 75.70%. This contributed to the annual value of $135,000 for FY2024, which is 91.74% down from last year.
  • As of Q3 2025, Phathom Pharmaceuticals' Capital Expenditures stood at $27,000, which was down 61.97% from $71,000 recorded in Q2 2025.
  • Phathom Pharmaceuticals' 5-year Capital Expenditures high stood at $939,000 for Q3 2023, and its period low was $5,000 during Q4 2024.
  • Moreover, its 3-year median value for Capital Expenditures was $44,000 (2025), whereas its average is $173,727.
  • Over the last 5 years, Phathom Pharmaceuticals' Capital Expenditures had its largest YoY gain of 666.67% in 2024, and its largest YoY loss of 98.95% in 2024.
  • Over the past 4 years, Phathom Pharmaceuticals' Capital Expenditures (Quarterly) stood at $412,000 in 2022, then climbed by 15.29% to $475,000 in 2023, then crashed by 98.95% to $5,000 in 2024, then crashed by 38.64% to $27,000 in 2025.
  • Its Capital Expenditures was $27,000 in Q3 2025, compared to $71,000 in Q2 2025 and $44,000 in Q1 2025.